Full Year 2023 Investor Presentation
157
Investor presentation
Full year 2023
In the US, net prices have declined in the last five years
The US population by health insurance
coverage
Insulin net prices¹ have declined
Net prices¹ across the full Novo
Nordisk portfolio² declined
Novo NordiskⓇ
110
7%
110
100
100
90
90
80
80
47%
70
70
60
60
46%
50
50
40
40
30
30
20
20
333 million people
10
10
0
0
Uninsured
2019
2020
2021 2022 2023
2019
2020
2021
2022
2023
Private insurance schemes
List prices
-
Net prices
-
List prices
-
Net prices
Goverment insurance schemes
¹Percentage change represents a sales weighted average list and net price for the respective calendar year compared to the sales weighted average list and net price for the prior year, indexed to base year 2019, and is not
reflective of the magnitude of individual list price actions 2NN US Product Portfolio is inclusive of Diabetes, Obesity and Rare disease products
Government insurance schemes cover Medicare, Medicaid and public exchanges, some of these with high deductibles.
Source: Novo Nordisk Annual Report 2023View entire presentation